MedTrace Logo

A Novel Combination Oral Agent to Treat Acne Vulgaris

NCT01301586 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-02-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate a novel, combination product for the treatment of acne vulgaris in females

Conditions

  • ACNE VULGARIS

Interventions

DRUG

Doxycycline and S-equol

Oral doxycycline and s-equol twice a day

DRUG

Doxycycline

ORAL DOXYCYCLINE TWICE A DAY

Sponsors & Collaborators

  • Nexgen Dermatologics, Inc.

    lead INDUSTRY

Principal Investigators

  • Joshua M Berlin, MD · Study Protocol, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301586 on ClinicalTrials.gov